In each country, usually approval for a clinical trial of a drug is issued by the national expert organization in the field of drug circulation (FDA, EMA, etc.) and the National Bioethics Commission. Is it necessary to create a separate specialized expert organization for the expertise of the advanced therapy medicinal products?